Year Established: 1817
Reveneus: $20,014 (-3%)
Pharma Revenues: $15,204 (flat)
Net Income: $2,373 (NM)
R&D: $3,619 (+3%)
TOP SELLING DRUGS
|Trajenta||type 2 diabetes||$1,650||18%|
|Jardiance||type 2 diabetes||$1,726||51%|
|Ofev||idiopathic pulmonary fibrosis||$1,299||25%|
Boehringer Ingelheim ended 2018 with flat pharma sales of $15.2 billion. As in previous years, the respiratory medicine Spiriva achieved the highest sales contributions with $2.8 billion, but this was an 11% drop from the year before due mostly to patent expiry. All other major products in Boehringer’s portfolio performed well. The anticoagulant Pradaxa was the next top seller with $1.8 billion in sales followed by type 2 diabetes drugs Jardiance, which grew 51% to $1.7 billion and Trajenta, which grew 18% to $1.6 billion. Rounding out the companies billion dollar performers was idiopathic pulmonary fibrosis treatment Ofev, which recorded $1.3 billion, up 25%.
In June 2018, Boehringer unveiled major investment plans on the biologics R&D front, pumping roughly $262 million into a new Biologicals Development Center (BDC) at the company’s site in Biberach, Germany. The BDC is part of the company’s long-term strategy to grow its biologics pipeline, specifically immune oncology and immunology. The company’s share of new biologics has been consistently increasing over the past few years and has now reached 40%.
The BDC will integrate biologics analytical and process development as well as manufacturing for clinical studies into one unit, while at the same time increasing development capacity. Following a staggered launch beginning in 2020, the new building will be home to 500 employees.
The new BDC adds to a number of major recent investments in its global biopharmaceuticals network aimed at increasing mammalian cell culture capabilities. This includes a large scale biopharmaceutical facility in Vienna, Austria, a new biopharmaceutical facility in Shanghai, China, and the expansion of existing large scale biopharmaceutical capacities in Fremont, CA.
On the cancer research front, Boehringer and Vanderbilt University expanded an existing collaboration to develop anti-cancer compounds, and formed a collaboration with OSE Immunotherapeutics to jointly develop OSE-172, a cancer immunotherapy.
In terms of filings, FDA granted Fast Track to Boehringer’s nintedanib for the treatment of systemic sclerosis with associated lung disease. In addition, positive results were reported from a Phase III study confirming that Cyltezo, the first biosimilar from Boehringer to be approved by FDA, is equivalent to Humira. This is the first U.S. study to investigate an interchangeability designation for an adalimumab biosimilar.